Dextech Medical (NGM:DEX) - Share price, News & Analysis

DEX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

DEX Stock Overview

Dextech Medical AB develops drug candidates for application in urological oncology, primarily for prostate cancer.

Rewards

Earnings have grown 8.7% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (SEK392K)

Does not have a meaningful market cap (SEK79M)

Shareholders have been diluted in the past year

Dextech Medical Competitors

Spago Nanomedical

OM:SPAGO

kr84.6m

Promore Pharma

OM:PROMO

kr72.2m

Active Biotech

OM:ACTI

kr276.9m

Prostatype Genomics

OM:PROGEN

kr66.7m

Price History & Performance

Summary of all time highs, changes and price drops for Dextech Medical
Historical stock prices
Current Share Price	kr4.08
52 Week High	kr33.20
52 Week Low	kr4.08
Beta	1.24
1 Month Change	-16.90%
3 Month Change	-37.23%
1 Year Change	-87.71%
3 Year Change	-94.52%
5 Year Change	-85.43%
Change since IPO	-59.20%

Recent News & Updates

Jan 10

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

	DEX	SE Biotechs	SE Market
7D	-9.5%	-2.1%	-0.1%
1Y	-87.7%	-22.1%	-22.0%

Return vs Industry: DEX underperformed the Swedish Biotechs industry which returned -22.1% over the past year.

Return vs Market: DEX underperformed the Swedish Market which returned -22% over the past year.

Price Volatility

Is DEX's price volatile compared to industry and market?
DEX volatility
DEX Average Weekly Movement	6.3%
Biotechs Industry Average Movement	9.7%
Market Average Movement	7.3%
10% most volatile stocks in SE Market	12.9%
10% least volatile stocks in SE Market	4.6%

Stable Share Price: DEX is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: DEX's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2004	1	Anders Holmberg	https://www.dextechmedical.com

Dextech Medical AB develops drug candidates for application in urological oncology, primarily for prostate cancer. Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast cancer. The company is also developing SomaDex, a drug candidate that is based on somatostatin body hormone to treat acromegaly, neuroendocrine tumors, and palliative therapy in advanced prostate cancer; CatDex, a preclinical stage drug candidate for instillation therapy of superficial bladder cancer; and PSMADex, a preclinical stage drug candidate that is used as a carrier molecule for the treatment of cancer expressing prostate-specific membrane antigen.

Dextech Medical Fundamentals Summary

How do Dextech Medical's earnings and revenue compare to its market cap?
DEX fundamental statistics
Market Cap	kr78.56m
Earnings (TTM)	-kr4.70m
Revenue (TTM)	kr391.98k

192.5x

P/S Ratio

-16.0x

P/E Ratio

Is DEX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
DEX income statement (TTM)
Revenue	kr391.98k
Cost of Revenue	kr1.51m
Gross Profit	-kr1.11m
Other Expenses	kr3.59m
Earnings	-kr4.70m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 30, 2022

Earnings per share (EPS)	-0.25
Gross Margin	-284.09%
Net Profit Margin	-1,200.13%
Debt/Equity Ratio	0.0%

How did DEX perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is DEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DEX?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for DEX. This is calculated by dividing DEX's market cap by their current preferred multiple.
What is DEX's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	kr78.56m

DEX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	101.2x
Enterprise Value/EBITDA	-6.9x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does DEX's PB Ratio compare to its peers?

DEX PB Ratio vs Peers

The above table shows the PB ratio for DEX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	5.3x
SPAGO Spago Nanomedical	0.5x	-13.5%	kr84.6m
PROMO Promore Pharma	2.2x	n/a	kr72.2m
ACTI Active Biotech	16.3x	-21.6%	kr276.9m
PROGEN Prostatype Genomics	2.1x	72.1%	kr66.7m
DEX Dextech Medical	1.8x	n/a	kr78.6m

Price-To-Book vs Peers: DEX is good value based on its Price-To-Book Ratio (1.8x) compared to the peer average (5.3x).

Price to Earnings Ratio vs Industry

How does DEX's PE Ratio compare vs other companies in the SE Biotechs Industry?

Price-To-Book vs Industry: DEX is good value based on its Price-To-Book Ratio (1.8x) compared to the Swedish Biotechs industry average (2.3x)

Price to Book Ratio vs Fair Ratio

What is DEX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DEX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.8x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate DEX's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of DEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DEX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DEX's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Dextech Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

33.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dextech Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Examine Dextech Medical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Dextech Medical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

8.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DEX is currently unprofitable.

Growing Profit Margin: DEX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: DEX is unprofitable, but has reduced losses over the past 5 years at a rate of 8.7% per year.

Accelerating Growth: Unable to compare DEX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DEX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).

Return on Equity

High ROE: DEX has a negative Return on Equity (-11.48%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Dextech Medical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: DEX's short term assets (SEK39.3M) exceed its short term liabilities (SEK200.0K).

Long Term Liabilities: DEX has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: DEX is debt free.

Reducing Debt: DEX has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DEX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DEX has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 23.3% each year

Discover healthy companies

Dividend

What is Dextech Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate DEX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DEX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DEX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DEX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DEX has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

18.6yrs

Average management tenure

CEO

Anders Holmberg (71 yo)

18.58yrs

Tenure

kr596,112

Compensation

Mr. Anders R. Holmberg, M.D. is the Founder of Dextech Medical AB (publ) and serves as its Chief Executive Officer and Managing Director and served as its President. Mr. Holmberg has been a Director at Dex...

Leadership Team

Experienced Management: DEX's management team is seasoned and experienced (18.6 years average tenure).

Board Members

Experienced Board: DEX's board of directors are considered experienced (9.4 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.9%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/09 00:00
End of Day Share Price	2022/08/09 00:00
Earnings	2022/03/31
Annual Earnings	2021/06/30